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Chongrui Xu, Qing Zhou and Yi-long Wu*Abstract
Background: In the first line treatment of non-small cell lung cancer (NSCLC), several clinical trials have shown that
not all NSCLC patients can benefit from treatment with tyrosine kinase inhibitors (TKIs) than receiving
chemotherapy. Some trials treated patients with TKI according to their clinical characteristics. A few studies only
chose patients with an epidermal grouth factor receptor (EGFR) mutation for TKI therapy. We aimed to determine
whether patients could be treated with TKIs based on clinical factors in the first-line setting.
Methods: We performed a meta-analysis of randomized trials involving patients with advanced NSCLC treated with
chemotherapy or TKIs by different selections. Efficacy outcomes of interest were the objective response rate (ORR),
progression-free survival (PFS) and the overall survival (OS) of each treatment arm.
Results: Four trials enrolled unselected patients, and two trials selected East Asian patients using the clinical factors
of gender and smoking history. Five trials chose patients with an EGFR mutation who were randomized for
treatment with TKI or chemotherapy. For unselected patients, the risk ratio (RR) of the ORR was 3.52, the hazard
ratio (HR) of the PFS was 1.29 and the HR of the OS was 1.35. For the clinically selected patients, the RR of the ORR
was 0.64. The HRs of the PFS and OS were 0.83 and 0.92, respectively. The ORR and PFS were better for TKIs than
for chemotherapy in patients with an EGFR mutation. The ORR was 0.47, and the HRs of the PFS and OS were 0.36
and 1.00, respectively.
Conclusions: Advanced NSCLC patients with an EGFR mutation benefit most from TKIs. EGFR-TKI treatment is
justified for patients with unknown EGFR status,and those who cannot tolerate chemotherapy owing to age, poor
performance status (PS) or other medical conditions, when selected according to clinical factors in the first-line
setting.
Keywords: Non-small cell lung cancer, Target therapy, Chemotherapy, Meta-analysisBackground
During the past 10 years, epidermal growth factor re-
ceptor (EGFR) tyrosine kinase inhibitors (TKIs) have
become the most promising treatment for advanced
non-small cell lung cancer (NSCLC). In 2003 and 2004,
gefitinib and erlotinib, respectively, were approved by
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reproduction in any medium, provided the oradvanced NSCLC patients who had previously received
chemotherapy. In 2005, the ISEL trial showed no bene-
fit for patients receiving gefitinib versus placebo [1],
while subgroup analysis showed a survival benefit for
gefitinib-treated patients in Asia [2]. The BR.21 study,
a trial focused on Caucasian patients, showed positive
results for patients who received erlotinib [3].
After TKIs were shown to be more effective than a
placebo treatment, several trials were performed to de-
termine whether TKIs were superior to chemotherapy in
advanced NSCLC patients [4-11]. Most trials showedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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survival (PFS), and the overall survival (OS) were similar
between chemotherapy and TKI arms in the second-line
setting. In the ISTANA and V-15-32 trials, the ORR of
chemotherapy was superior to that of TKIs. When unse-
lected NSCLC patients received TKIs in the first–line
setting, the ORR, PFS, and OS were not better than
those for standard chemotherapy. These results indicate
that not all NSCLC patients can benefit from TKIs.
In 2004, Lynch et al. [12] and Paez et al. [13] found
that patients who harbored an active mutation in EGFR
derived greater benefit from TKI treatment. Several cli-
nical trials have shown that patients with an EGFR mu-
tation responded better and had a better PFS than
patients carrying wild-type EGFR, when receiving EGFR-
TKIs compared with a placebo. In 2010, two randomized
trials in Japan and one randomized trial in China com-
pared TKI treatment and chemotherapy in patients with
EGFR mutations. The results confirmed that NSCLC
patients with EGFR mutations can realize greater bene-
fits from TKIs than from chemotherapy as first-line
treatment. Thus, most guidelines have been updated
with the consensus that an EGFR mutation is the stron-
gest predictive factor for TKI treatment. In the clinic,
however, not all NSCLC patients have adequate tissue or
specimens for mutation detection, and not all patients
can tolerate chemotherapy. Whether patients with un-
known EGFR status should receive TKIs in the first-line
setting is still controversial. EGFR-TKIs were suitable for
all patients in the second-line setting, based on clinical
practice. It is easy for clinicians to treat patients with
TKIs according to clinical factors. Is it reasonable to
choose patients for TKI treatment according to specific
clinical factors?
We performed a meta-analysis of the response, PFS,
and survival data between unselected, clinically selected,
and EGFR mutation-selected trials to determine the best
method for choosing patients who would benefit from
TKI therapy in clinical practice.
Methods
Search strategy
The efficacy outcomes of interest were the ORR
(complete and partial response) based on the Response
Evaluation Criteria in Solid Tumors (RECIST), the PFS,
and the OS for each treatment arm.
To find relevant articles, we searched MEDLINE, Clinical-
Trials.gov, the Cochrane Library, abstracts from the
World Conference for Lung Cancer (WCLC) and the an-
nual meetings of the American Society of Clinical Onco-
logy (ASCO) and European Society for Medical Oncology
(ESMO). The medical subjects heading (MeSH) terms
used for keyword and text word searching included
advanced non-small cell lung cancer, gefitinib, erlotinib,and epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor. In addition to computer-based searches,
the reference lists in reviews and original papers were
scanned to look for missing trials. No language restrictions
were applied.
Study selection
We considered all prospective, randomized, controlled
trials published in peer-reviewed journals or presented
at meetings of ASCO, ESMO or WCLC before 2012 in
which stage IIIB/IV or post-operational recurrent
NSCLC (including adenocarcinoma, squamous cell car-
cinoma, and large cell carcinoma) patients were pro-
spectively randomized to receive gefitinib or erlotinib
versus chemotherapy. Only articles published before De-
cember 31, 2011 were included. Whenever multiple
reports of the same research were encountered, we
retained only the report with the longest follow-up (lar-
gest number of events) to avoid duplication of informa-
tion. We excluded dose-escalating studies, phase I or I/II
trials, trials with placebo in the control arms, and studies
focusing on the frequency of EGFR gene mutation and
its correlation with clinical pathological status. Studies
that did not clearly present ORR, PFS, or OS informa-
tion were also excluded, as were studies with “triplet”
chemotherapy regimens or sequential or combination
therapy involving gefitinib or erlotinib with other che-
motherapeutic agents.
Trials that enrolled all NSCLC patients were consid-
ered unselected trials. Trials that enrolled NSCLC
patients with specific clinical characteristics such as gen-
der, smoking history, ethnicity, or pathologic type were
clinically selected trials. Trials that enrolled only patients
with an EGFR mutation were EGFR mutation-selected
trials.
Statistical methods
Treatment arms with both chemotherapy and TKIs were
combined regardless of dosage, regimen, or previous
treatment. Patients obtaining complete response or par-
tial response were considered as ORR. ORR data esti-
mates of the treatment effects were obtained from the
number of events reported in each arm of the trials. For
time-to-event data PFS and OS, the log hazard ratios
(HRs) and their variances were estimated using the
methods proposed by Pignon and Hill [14]. HRs with
95% CIs were calculated using an inverse variance
method.
The I-squared statistic was employed to assess va-
riability across studies attributable to heterogeneity. He-
terogeneity was considered significant at a p-value of the
I-squared statistic higher than 25%. We interpreted a
random-effects model because between-study heteroge-
neity was anticipated.
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with the exception of those for heterogeneity. ORR of
the patients was analysis of the variance with different




We identified 17 randomized studies involving 8537
patients with advanced NSCLC, from computerized li-
terature databases, reference lists of systematic reviews,
and relevant articles (Figure 1). Seven trials were
excluded as six used a placebo in the control arm and
one combined chemotherapy with erlotinib treatment.
The other 10 studies, published between 2006 and 2011,
were included. The number of subjects in these studies
ranged from 35 to 1466, for a total of 3045 patients. All
of the studies were randomized trials with head-to-head
comparisons of various chemotherapeutic regimens ver-
sus TKIs (Table 1).
Efficacy comparison
Gefitinib was the first TKI approved in non-small cell
lung cancer and now is still approved in East-Asia, so
several trials tried to treat patients in the first-line with
Gefitinib. Trials performed in the Caucasian patients
chose Erlotinib recently. We integrate the two TKIs to-
gether when performing the analysis.
Four studies of randomized NSCLC patients were
based on no particular patient criteria in the first-line
setting. Among them, three used gemcitabine, vinorel-
bine, or paclitaxel plus carboplatin. All trials reported10RCTs matching inclus




17 RCTs identified for the
4 trials evaluable for ORR, 1094 patients
2 trials evaluable for PFS, 299 patients
3 trials evaluable for OS, 1059 patients
2 trials evaluable for O
2 trials evaluable for P
2 trials evaluable for O
Figure 1 Outline of the search flow diagram.the ORR. PFS was available for two trials; and OS for
three trials.
Two trials, IPASS and First-SIGNAL, selected patients
according to clinical criteria. The IPASS trial chose East
Asian adenocarcinoma patients who had never smoked
or were former light smokers. ORR, PFS and OS of the
EGFR status unknown patients had been reported. The
First-SIGNAL trial enrolled East Asian adenocarcinoma
patients who had never smoked. Both trials used gefiti-
nib as the treatment arm; the control arm was paclitaxel
plus carboplatin in IPASS, and gemcitabine plus cisplatin
in First-SIGNAL.
Two trials from Japan reported results in patients with
an EGFR mutation randomized to receive gefitinib or
chemotherapy; both trials used gefitinib as the treatment
arm; docetaxel plus cisplatin and paclitaxel plus carbopla-
tin were used in the control arms. The IPASS trial also
reported the results of an EGFR mutation subgroup and
was included in the meta-analysis of the EGFR mutation
selection trials. Last year, the EURTAC trial reported
results at the ASCO annual meeting and this was pub-
lished this year. Patients with and EGFR mutation received
erlotinib or platinum-based doublet. The OPTIMAL trial
treated patients with an EGFR mutation randomly either
with erlotinib or gemcitabine and carboplatin.
The ORR of the TKIs in the unselected, clinical
selected and EGFR mutation selected was 5%, 47.7% and
69.6%, respectively. (p = 0.049)
For the unselected first-line trials, the risk ratio (RR)
of the ORR was 3.52 [95% CI, 2.41–5.15] (Figure 2). The
HR of the PFS was 1.29 [95% CI, 1.00–1.66] (Figure 2),
and the HR of the OS was 1.35 [95% CI, 1.13–1.61]
(Figure 2).ion criteria, 3045patients
ed  (2 trials)
ients
Mutation selected (5 trials)
858 patients
 meta-analysis, 8537 patients 
RR, 1093 patients
FS, 1093 patients
S, 1093 patients 
5 trials evaluable for ORR, 858 patients 
5 trials evaluable for PFS, 858 patients
3 trials evaluable for OS, 586 patients 
Table 1 Characters of the eligible trials
Author Year Pts Treatment arm Control arm
Unselected
Lilenbaum, R. [10] 2008 103 Erlotinib Paclitaxel + Carboplatin
Crino, L. (INVITE) [6] 2008 196 Gefitinib Vinorelbine
Agarwal, S. [4] 2010 35 Gefitinib Gemcitabine + Carboplatin
Gridelli, C. (TORCH)[15] 2010 760 Erlotinib Vinorelbine + Carboplatin
Clinical-Selected
Lee, J. S. (First-SIGNAL) [16] 2009 313 Gefitinib Gemcitabine + Cisplatin
Mok, T. S. (IPASS) [17,18] 2009 780 Gefitinib Paclitaxel + Carboplatin
EGFR mutation Selected
Mitsudomi, T. (WJTOG3405) [19] 2010 177 Gefitinib Docetaxel + Cisplatin
Maemondo, M. (NEJSG) [20] 2010 230 Gefitinib Paclitaxel + Carboplatin
Mok, T. S. (IPASS) [17,18] 2009 261 Gefitinib Paclitaxel + Carboplatin
Zhou, C. (OPTIMAL) [21] 2011 165 Erlotinib Gemcitabine + Carboplatin
Rosell, R. (EURTAC) [22] 2011 174 Erlotinib Platium based
Xu et al. Journal of Hematology & Oncology 2012, 5:62 Page 4 of 9
http://www.jhoonline.org/content/5/1/62When patients with unknown EGFR status were
chosen to receive TKIs or chemotherapy according to
clinical factors, the RR of the ORR was 0.64 [95% CI,
0.52–0.79], favoring TKI (Figure 3). The HRs of the PFS
and OS were 0.83 [95% CI, 0.74–0.93] (Figure 3) and
0.92 [95% CI, 0.79–1.07] (Figure 3), respectively.
The ORR and PFS were better for TKIs than for
chemotherapy in patients with an EGFR mutation. The
ORR was 0.47 [95% CI, 0.41–0.55] (Figure 4), and the
HRs of the PFS and OS were 0.36 [95% CI, 0.31–0.43]
(Figure 4) and 1.00 [95% CI, 0.79–1.27] (Figure 4),
respectively.
Discussion
EGFR-TKIs are the most promising development in the
treatment of advanced NSCLC. Clinical trials comparing
TKIs and placebos have produced controversial results.
It seems that not all NSCLC patients benefit from these
drugs. Different selection criteria for patients will pro-
duce different results.
The ORR of TKIs was higher in EGFR mutation
selected groups than the other two groups, but it was
undirected comparison. To find out how to choose TKIs
or chemotherapy in different selections, TKIs versus
chemotherapy was analyzed.
Four trials compared TKIs with chemotherapy in the
first line setting for unselected NSCLC patients. The
control arm involved standard chemotherapeutic regi-
mens such as paclitaxel plus carboplatin or gemcitabine
plus carboplatin, vinorelbine, or docetaxel. The ORR for
chemotherapy was superior to the ORR for TKIs. The
OS and especially the PFS tended to benefit from
chemotherapy. The HR of the ORR was 3.52, and the
PFS 1.29, OS 1.35 ———— all well above 1.0. Theseresults indicate that EGFR-TKIs may be harmful to
unselected patients in the first-line setting. In this situa-
tion, chemotherapy should still be used as the standard
treatment for unselected patients.
Five trials reported the results of TKI treatment versus
chemotherapy in patients with an EGFR mutation, show-
ing that these patients benefitted more from TKI treat-
ment based on both the response and PFS. The results
of these five trials confirm the superiority of TKIs com-
pared with chemotherapy for patients with an EGFR
mutation. The OS for patients with an EGFR mutation
was similar to chemotherapy, but there are too many
factor will interfere the survival. The interference of the
survival not only on the patients received TKIs in the
second line but also the different chemotherapy regimen
or some patients without second line therapy. The
results of the meta-analysis confirmed the survival of the
TKIs is similar with the chemotherapy in patients with
EGFR mutations while the ORR and PFS of TKIs were
dramatically superior. Patients should receive TKI treat-
ment when their EGFR mutation status is confirmed.
In clinical practice, however, not all patients can
undergo EGFR gene analysis. Salto-Tellez et al. [23] esti-
mated that the proportion of non-squamous NSCLC
patients tested for EGFR mutations varied from 30% to
80% in East Asia. Furthermore, some patients with poor
performance status or with comorbidities cannot tolerate
chemotherapy. Determining whether EGFR-TKIs should
be used in the first-line setting for patients with un-
known EGFR status and a performance status >2 is an
important issue. Two trials compared TKIs and chemo-
therapy in patients selected according to specific clinical
characteristics. Both studies were performed in East Asia
and enrolled patients with an adenocarcinoma subtype
Figure 2 Meta-analysis of the first line trials in unselected patients.
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Figure 3 Meta-analysis of the trials in clinical selected patients with EGFR unknown status.
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Figure 4 Meta-analysis of the trials in EGFR mutation selected patients.
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smokers. A meta-analysis of the two trials showed that
the patients chosen in this way had a greater response
and better PFS with TKI treatment than with chemo-
therapy. In the TOPICAL trial [24], when all NSCLC
patients with poor performance status or who were unfit
for chemotherapy were given erlotinib or placebo in the
first-line setting, the OS did not improve with erlotinib;
however, an analysis by gender showed that the female
patients benefited from erlotinib in terms of PFS and
OS, while the male patients did not. Thus, in some spe-
cial situations involving patients with unknown EGFR
status or who are not fit for chemotherapy, a trial of
EGFR-TKI may be reasonable according to clinical cri-
teria, provided that the patient and family members have
been informed of the possible worsening of symptoms
and disease based on the IPASS and TORCH findings.
This meta-analysis showed that groups of advanced
NSCLC patients selected according to different criteria
will show differential benefits from TKIs compared with
standard chemotherapy. However, this meta-analysis did
not consider involving individual patient data, and only
two trials performed in East Asia focused on clinical se-
lection of patients. Most trials only report the clinical
characteristics and total response of the EGFR mutation
and wild type patients. The different clinical factors may
have different influence on the results while this meta-
analysis cannot interpret. More trials are needed involving
patients with specific clinical characteristics to confirm
these findings.
Conclusions
Our meta-analysis indicates that among NSCLC patients,
advanced NSCLC patients with EGFR gene mutations
would benefit most from TKI treatment, especially in the
first-line setting. Nevertheless, EGFR-TKI treatment is jus-
tified for patients with unknown EGFR status, those who
cannot tolerate chemotherapy owing to advanced age or
who have poor performance status, and those with other
medical conditions, when selected according to clinical
factors.
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